ACE-011

DRUG3 trials

Sponsors

Celgene, Massachusetts General Hospital

Conditions

Multiple MyelomaMyelodysplastic Syndrome

Phase 1

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, not recruitingNCT01562405

Massachusetts General HospitalMultiple Myeloma

Start: 2012-05-01End: 2027-12-01Updated: 2026-06-25

Phase 2

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

CompletedNCT00747123

CelgeneMultiple Myeloma

Start: 2008-09-01End: 2009-08-01Updated: 2024-10-03

Unknown Phase

Expanded Access for ACE-011

CelgeneMyelodysplastic Syndrome

Updated: 2020-07-17

Related Papers

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood2015-12-0310 citations

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.

2013-02-1832 citations